



CPK Now Overview

Prepared For:

Date: June 18th 2026

IVDS's novel biomarker testing platform will improve the treatment paradigm for numerous conditions including LC-FAOD

IVDS Background



IVDS was founded in 2017 by Founder & CEO Rob Harper after ~30 years leading R&D



IVDS built a novel biomarker testing platform applicable for numerous conditions



Lead program PKU Now, accurately, instantly and easily measures Phe; anticipated approval in 2027



CPK Now will do the same for CK levels with clinical trial initiation in 2027

\$10M

Non-dilutive Funding

14

Provisional Patents

>150

Highly interested
LC-FAOD patients

100s

Of verification /
validation studies

>2,000ft²

Manufacturing space



LC-FAOD is a devastating condition affecting thousands, who experience chronic pain and frequent rhabdomyolysis

Overview

- Long chain fatty acid oxidative disorders (LC-FAODs) are rare but devastating metabolic conditions that prevent the body from converting fat into energy


Occurrence

- Diagnosed prevalence ~3K in US & ~85K WW; 1 in 9K incidence (implying high underdiagnosis)

Clinical Burden

- Patients experience a range of symptoms, but musculoskeletal are most common
- Most patients experience muscle pain daily and dozens of CPK elevations along with multiple rhabdomyolysis events in any given year

Symptoms



[illegible]

```
graph TD; A[Patient Travels To Clinic or ER] --> B[Clinician Orders Serum CPK Test]; B --> C[Phlebotomist Draws Patient Blood]; C --> D[Pre-analytical Processing in Lab]; D --> E[Lab Analyzes Sample]; E --> F[Lab Sends Results To Clinician]; F --> G[Clinician Sends Results To Patient];
```

The flowchart illustrates the diagnostic process for a patient with chest pain. It begins with the patient traveling to the clinic or ER, followed by the clinician ordering a serum CPK test. A phlebotomist then draws the patient's blood, which undergoes pre-analytical processing in the lab. The lab analyzes the sample and sends the results to the clinician, who then sends the results to the patient.

~2 days to ~2 weeks

– *FAOD Patient*

CPK Now is the first portable monitor providing accurate CK results instantly enabling better health outcomes

CPK Now




IVDS's proprietary blood separation technique allows for the simultaneous measurement of multiple important biomarkers

IVDS OnSight Meter





OnSight Strip



- 1 **Uniform Spreading**
Hydrophilic mesh evenly distributes blood cells across the surface
- 2 **Primary Blood Separation**
Glass fiber membrane that separate ~90% blood cells from plasma
- 3 **Secondary Blood Separation**
Polyethersulfone membrane ensures 100% plasma cell separation
- 4 **Detection**
An anisotropic polysulfone layer coated with a proprietary reagent
- 5 **Synchronous Detection**
Three LEDs allow for simultaneous testing of multiple analytes

CPK Now has demonstrated strong concordance in pre-clinical setting across a wide CPK range (0-60K U/L) in <5 minutes


Preliminary CPK Now Data on Spiked Blood Samples
15 Concentrations, n=3 per Concentration, 45 Determinations




IVDS has overcome one of the most common challenges preventing point of care CK measurement- myokinase interference

 Myokinase (adenylate kinase) is another enzyme like CK, ubiquitous in muscle cells that unfortunately 'tricks' CK tests

 IVDS team has uncovered an innovative approach to preventing this challenge through chemistry




The CPK Now can be programmed with the latest clinical guidelines, so patients are empowered to make the right decision



Note: This information is for internal IVDS use only. This is not meant to be a guideline for patients in regard to clinical care. This is an evolving process. Please work with your genetics team to navigate when hospitalizations are necessary

Patient results go to the 'CPK Connect' mobile application which provides unprecedented insights to optimize health



CPK Connect v1.0 Features

- Longitudinal Analyses
- Data Visualization
- Data Sharing
- Progress Monitoring
- Gamified Notifications

CPK Connect v3.0 Features

- Educational Resources
- Community Support
- Meal Planning

CPK Connect v2.0 Features

- Medication Management
- Dietary Tracking
- Symptom Tracking
- Wearables Integration

ILLUSTRATIVE

Patients are highly enthusiastic about the CPK now

Patient Feedback

>90%
of patients strongly agreed with these statements

- I would learn the root of my pain symptoms
- I would learn how levels responds to diet, activity & meds
- It would prevent unnecessary trips to the ER/Hospital
- We could treat the rhabdomyolysis in a timelier manner
- I would take more educated decisions with our HCPs

~67%
expressed strong desire to acquire CPK Now when asked to share “feedback / concerns / questions”

- Very excited about the idea of this device and would love to have this.

This would be life altering for my son

I would love to have this for my family!!!

How soon can we PLEASE get one?!

Please do this, I've wanted one for 20yrs

No Qs just excited this may be a reality.

None!! I'll take one!!

Thank for investing in our rare community and offering possibilities for a better QoL.
- I would love for something like this to come out! It would be so much easier!

This sounds incredible!

When would this be available to us?

This would be absolutely amazing

Potential features sound amazing!

Is this device available now?

When can I get one?!


None just when can we get it

This would be amazing to have at home!


This is my dream. I would happily sign up to be in a study for it or be a beta tester

The CPK Now enables >2x more testing than today, enabling improved outcomes

Testing Frequency Today



Testing Frequency w. CPK Now



Sources: 2024 MitoAction Quantitative Survey (N=167)

Leading clinical, industry and advocacy influencers are excited about the CPK Now

"Your preliminary data on the meter development look very promising and am confident of your ability to complete this"

Nicola Longo, MD, PhD

Professor and Chief, Division of Clinical Genetics, UCLA

UCLA Health



"A home CPK monitor would revolutionize clinicians' ability to safely treat patients from home instead of the hospital, creating a true paradigm shift"

Kira Mann

CEO MitoAction

mito
ACTION



"Rhabdomyolysis is a major cause of morbidity and mortality in LC-FAODs. Development of a POC meter for rapid, accurate and reproducible detection of CPK from a few drops of blood will indeed be a paradigm shift"

Jerry Vockley, MD, PhD

Director of Genetic Medicine, Metabolic Disease FDA Advisory Committee

UPMC
LIFE CHANGING MEDICINE



"We believe that providing real-time results for blood CPK values would have a significant, positive impact on LC-FAOD patients and save hospital visits and costs to both patients and caregivers."

Ellen Struif

Global Acceleration Unit Director

NUTRICIA



"Home monitoring would revolutionize care for these patients by giving them and caregivers clearer treatment strategies for when rest and hospitalization is needed."

Bernard Cuenoud

Head of Global Research & Clinical Development


Nestlé



"I am enthusiastic about the potential of the CPK Now device to transform the standard of care for patients with LCFAODs and other conditions that require close monitoring of CPK levels"

Mary Kate LoPiccolo MD


Assistant Professor Department of Genetics


**Mount
Sinai
Hospital**



CPK Now brings significant value to the entire LC-FAOD ecosystem

LC-FAOD Market Map



Reasons to Partner

- | | |
|-----------------------|--------------------------------|
| ✓ Enhance Patient QoL | ✓ Expand Reach |
| ✓ Identify Responders | ✓ Differentiate Offering |
| ✓ Optimize Dosing | ✓ Accelerate R&D |
| ✓ Monitor Outcomes | ✓ Improve Reimbursement |
| ✓ Increase Compliance | ✓ Generate Real-world Evidence |

CPK Now is anticipated to enter pivotal studies in 2027*

Major Milestones

Historical Accomplishments

- ✓ \$10M in non-dilutive funding
- ✓ Encouraging early CPK Now data
- ✓ PKU Now 510K in 2027
- ✓ Supportive patient advocates
- ✓ Robust patent portfolio
- ✓ Talented cross functional team
- ✓ Custom R&D & manufacturing lab
- ✓ Trusted expert advisors

	2026				2027				2028			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Research	Verification & Validation											
Clinical							Pivotal study					
Regulatory									510K			

*Timing is preliminary based on best internal estimates



In Vitro Diagnostic Solutions

Join Us in Transforming Inherited Metabolic Disorder Care